George Au-Yeung1, Penelope M Webb2, Anna DeFazio3, Sian Fereday4, Mathias Bressel5, Linda Mileshkin6. 1. Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. Electronic address: george.au-yeung@petermac.org. 2. Gynaecological Cancers Group, QIMR Berghofer Institute of Medical Research, Brisbane, Queensland, Australia. 3. Department of Gynaecological Oncology and Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, NSW, Australia. 4. Cancer Genomics Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. 5. Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. 6. Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Abstract
OBJECTIVES: Obesity is an increasing health problem that is reported to influence chemotherapy dosing. The extent to which this occurs and whether this affects outcomes in ovarian cancer was unclear. To describe chemotherapy dosing practices in normal, overweight and obese patients treated for FIGO Stage III/IV serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). To evaluate the relationship between body mass index (BMI), dose intensity of chemotherapy received, overall survival (OS) and progression free survival (PFS). METHODS: Patient characteristics including age, height, weight, FIGO stage, serum creatinine, primary chemotherapy received and outcome data were extracted from medical records and entered into the AOCS database. Outcomes were analysed against BMI and relative dose intensity (RDI) received, based on calculations derived from a standard regimen (carboplatin AUC 5 and paclitaxel 175mg/m(2)). RESULTS: 333 women were included in the analysis. 27% were overweight and 21% were obese. In cycle 1 66% of obese patients received carboplatin doses more than 5% below their optimal calculated dose, and 32% received sub-optimal paclitaxel doses, compared to 25% and 13% of normal weight patients respectively. Obese women were more likely to have received <85% RDI for carboplatin compared to normal weight women (p<0.001). BMI group and RDI of carboplatin and paclitaxel were not predictors of OS. Women who received less than 85% RDI for carboplatin had a worse PFS (univariate analysis, median PFS 11 versus 15 months; p=0.04). There was no significant association between RDI and OS or PFS in multivariate analysis. CONCLUSIONS: Obesity is common in ovarian cancer patients, and commonly results in lower chemotherapy dosing than recommended. Analysis of chemotherapy dosing from this study suggests that reduced dose intensity of carboplatin, which was more common in obese women, may impact on PFS in patients with advanced serous ovarian cancer.
OBJECTIVES:Obesity is an increasing health problem that is reported to influence chemotherapy dosing. The extent to which this occurs and whether this affects outcomes in ovarian cancer was unclear. To describe chemotherapy dosing practices in normal, overweight and obesepatients treated for FIGO Stage III/IV serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). To evaluate the relationship between body mass index (BMI), dose intensity of chemotherapy received, overall survival (OS) and progression free survival (PFS). METHODS:Patient characteristics including age, height, weight, FIGO stage, serum creatinine, primary chemotherapy received and outcome data were extracted from medical records and entered into the AOCS database. Outcomes were analysed against BMI and relative dose intensity (RDI) received, based on calculations derived from a standard regimen (carboplatin AUC 5 and paclitaxel 175mg/m(2)). RESULTS: 333 women were included in the analysis. 27% were overweight and 21% were obese. In cycle 1 66% of obesepatients received carboplatin doses more than 5% below their optimal calculated dose, and 32% received sub-optimal paclitaxel doses, compared to 25% and 13% of normal weight patients respectively. Obesewomen were more likely to have received <85% RDI for carboplatin compared to normal weight women (p<0.001). BMI group and RDI of carboplatin and paclitaxel were not predictors of OS. Women who received less than 85% RDI for carboplatin had a worse PFS (univariate analysis, median PFS 11 versus 15 months; p=0.04). There was no significant association between RDI and OS or PFS in multivariate analysis. CONCLUSIONS:Obesity is common in ovarian cancerpatients, and commonly results in lower chemotherapy dosing than recommended. Analysis of chemotherapy dosing from this study suggests that reduced dose intensity of carboplatin, which was more common in obesewomen, may impact on PFS in patients with advanced serous ovarian cancer.
Authors: Elisa V Bandera; Valerie S Lee; Lorna Rodriguez-Rodriguez; C Bethan Powell; Lawrence H Kushi Journal: JAMA Oncol Date: 2015-09 Impact factor: 31.777
Authors: Elisa V Bandera; Valerie S Lee; Lorna Rodriguez-Rodriguez; C Bethan Powell; Lawrence H Kushi Journal: Clin Cancer Res Date: 2016-08-12 Impact factor: 12.531
Authors: Sarah A Purcell; Sarah A Elliott; Candyce H Kroenke; Michael B Sawyer; Carla M Prado Journal: Curr Oncol Rep Date: 2016-02 Impact factor: 5.075
Authors: Renée T Fortner; Elizabeth M Poole; Nicolas A Wentzensen; Britton Trabert; Emily White; Alan A Arslan; Alpa V Patel; V Wendy Setiawan; Kala Visvanathan; Elisabete Weiderpass; Hans-Olov Adami; Amanda Black; Leslie Bernstein; Louise A Brinton; Julie Buring; Tess V Clendenen; Agnès Fournier; Gary Fraser; Susan M Gapstur; Mia M Gaudet; Graham G Giles; Inger T Gram; Patricia Hartge; Judith Hoffman-Bolton; Annika Idahl; Rudolf Kaaks; Victoria A Kirsh; Synnove Knutsen; Woon-Puay Koh; James V Lacey; I-Min Lee; Eva Lundin; Melissa A Merritt; Roger L Milne; N Charlotte Onland-Moret; Ulrike Peters; Jenny N Poynter; Sabina Rinaldi; Kim Robien; Thomas Rohan; Maria-José Sánchez; Catherine Schairer; Leo J Schouten; Anne Tjonneland; Mary K Townsend; Ruth C Travis; Antonia Trichopoulou; Piet A van den Brandt; Paolo Vineis; Lynne Wilkens; Alicja Wolk; Hannah P Yang; Anne Zeleniuch-Jacquotte; Shelley S Tworoger Journal: Int J Cancer Date: 2019-01-14 Impact factor: 7.396
Authors: Albina N Minlikeeva; Rikki Cannioto; Allan Jensen; Susanne K Kjaer; Susan J Jordan; Brenda Diergaarde; J Brian Szender; Kunle Odunsi; Hani Almohanna; Paul Mayor; Kirsten Starbuck; Emese Zsiros; Elisa V Bandera; Daniel W Cramer; Jennifer A Doherty; Anna DeFazio; Robert Edwards; Ellen L Goode; Marc T Goodman; Estrid Høgdall; Keitary Matsuo; Mika Mizuno; Christina M Nagle; Roberta B Ness; Lisa E Paddock; Celeste L Pearce; Harvey A Risch; Mary Anne Rossing; Kathryn L Terry; Anna H Wu; Francesmary Modugno; Penelope M Webb; Kirsten B Moysich Journal: Cancer Causes Control Date: 2019-03-23 Impact factor: 2.532
Authors: C M Nagle; S C Dixon; A Jensen; S K Kjaer; F Modugno; A deFazio; S Fereday; J Hung; S E Johnatty; P A Fasching; M W Beckmann; D Lambrechts; I Vergote; E Van Nieuwenhuysen; S Lambrechts; H A Risch; M A Rossing; J A Doherty; K G Wicklund; J Chang-Claude; M T Goodman; R B Ness; K Moysich; F Heitz; A du Bois; P Harter; I Schwaab; K Matsuo; S Hosono; E L Goode; R A Vierkant; M C Larson; B L Fridley; C Høgdall; J M Schildkraut; R P Weber; D W Cramer; K L Terry; E V Bandera; L Paddock; L Rodriguez-Rodriguez; N Wentzensen; H P Yang; L A Brinton; J Lissowska; E Høgdall; L Lundvall; A Whittemore; V McGuire; W Sieh; J Rothstein; R Sutphen; H Anton-Culver; A Ziogas; C L Pearce; A H Wu; P M Webb Journal: Br J Cancer Date: 2015-07-07 Impact factor: 7.640